Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

UK pharmaceutical firm Clinigen agrees to $1.6 billion take-private deal

Stock MarketsDec 08, 2021 10:05
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

By Pushkala Aripaka

(Reuters) - Clinigen on Wednesday agreed to be bought by UK-based Triton Investment Management in a deal that values the pharmaceutical services group at about 1.2 billion pounds ($1.6 billion), making it the latest British company to go private.

Last week, Clinigen confirmed advanced talks with the private-equity firm over a possible deal. Pressure has built on the company since Elliott Management raised its stake in recent weeks amid reports the activist investor was seeking to break up Clinigen.

Triton has offered 883 pence per share in cash, with shareholders also eligible to receive a previously declared final dividend of 5.46 pence per Clinigen share, the companies said.

"The Clinigen Board believes (Triton's) offer represents an exceptional opportunity for Clinigen shareholders ... We are therefore unanimously recommending it to our shareholders," Chairman Elmar Schnee said in a statement.

Shares of London-listed Clinigen jumped 10% to 900 pence by 0849 GMT, indicating shareholders could be expecting a better proposal. Analysts including Liberum's Alistair Campbell, however, thought a higher counter bid was unlikely.

"Though we do see intrinsic value in the portfolio, a public market turnaround is perhaps not the most expedient way to achieve this, and we see this as a good offer for shareholders," Peel Hunt analysts said in a note.

Private equity buyouts surged 133% to $818 billion globally in the first nine months of the year as investment firms rushed to deploy cash, often paying rich prices to take assets off the public markets.

British supermarket group Morrisons was bought for $10 billion by Clayton, Dubilier & Rice, beating Softbank-owned Fortress Investment Group in a head-to-head auction in October.

Including Wednesday's gains, Clinigen's shares are up about 33% this year.

Clinigen helps drug developers manage clinical supplies and provides real-world data about medicines, and would be the latest addition to Triton's burgeoning healthcare portfolio.

($1 = 0.7549 pounds)

UK pharmaceutical firm Clinigen agrees to $1.6 billion take-private deal
 

Related Articles

Sigma becomes first new LME ring member in 15 years
Sigma becomes first new LME ring member in 15 years By Reuters - Jan 26, 2022

By Eric Onstad LONDON (Reuters) -Sigma Broking Ltd became the first new ring trading member of the London Metal Exchange in 15 years on Wednesday amid doubts about the future of...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email